Sponsors (8)
The bill shifts marijuana from strict federal prohibition toward a regulated interstate market that expands state and tribal autonomy, consumer safety oversight, and business normalization — but it adds federal taxes, regulatory and enforcement complexity, and potential public-health/diversion risks that could raise costs and create uneven protections unless carefully implemented.
State and tribal governments — and people and businesses that follow their rules — will largely avoid federal CSA prosecution and can set local time, place, and manner restrictions (zoning, school buffers), increasing legal certainty and local control.
Compliant, state-licensed businesses gain major economic benefits: access to banking/AML relief, protection from civil forfeiture, eligibility for tax deductions otherwise barred by IRC §280E, and clearer ability to engage in interstate commerce, improving profitability and investment.
Consumers and public health gain clearer federal safety standards — FDA oversight, manufacturing and contaminant-testing requirements, youth marketing/postmarket-reporting rules — plus a federal evidence-based study on marijuana-impaired driving to inform safety policy.
Businesses, states, and tribes will face substantial new federal compliance costs and regulatory complexity (testing, labeling, FDA pre/postmarket rules, TTB administration, interstate rules) that raise operating costs and may advantage larger firms over small/craft operators.
A new federal excise tax will raise costs for consumers and licensed businesses and could keep legal prices higher than illicit-market prices, limiting licensed market growth and consumer savings.
Differing state, tribal, and federal standards (and retained federal offenses) create legal and enforcement uncertainty across jurisdictions, complicating policing, prosecutions, and business operations and forcing litigation to sort conflicts.
Based on analysis of 9 sections of legislative text.
Exempts state/tribe‑compliant marijuana from most federal drug laws, enables interstate transport between permissive jurisdictions, creates FDA product rules, and funds federal oversight via an excise tax.
Official title: To amend the Controlled Substances Act to provide for a new rule regarding the application of the Act to marijuana, and for other purposes.
Introduced April 17, 2025 by David Joyce · Last progress April 17, 2025
Creates a federal framework that largely removes federal criminal penalties for marijuana activities that comply with state or tribal law, allows interstate transport between jurisdictions that permit cannabis, and establishes federal regulatory and consumer-safety rules for marijuana products under FDA and the FD&C Act. It also authorizes a federal excise tax to fund regulatory oversight and requires agency rulemaking and a GAO study on traffic safety within set deadlines. The bill amends the Controlled Substances Act to exempt state- and tribe-compliant marijuana from CSA coverage, narrows certain federal enhanced-penalty provisions, defines how marijuana products are regulated under FDA authorities, protects compliant transactions from specific federal criminal, forfeiture, tax, and anti‑money‑laundering penalties, and affirms tribal regulatory self-determination in a nonbinding sense of Congress.